A radiofrequency-based renal denervation system for uncontrolled hypertension got a cool reception from FDA advisors who nevertheless left the door open for regulatory approval. On Wednesday, the ...

Credit: Recor Medical. The approval was based on data from the RADIANCE II trial which included patient with mild to moderate hypertension who were adequately controlled with medications. The Food and ...

Credit: Medtronic. The Simplicity Spyral RDN system is designed to lower BP by delivering radiofrequency energy through the wall of the renal artery to denervate the kidney from sympathetic nerve ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

A version of this article was published by HCPLive®. This version has been lightly edited. The FDA has approved the Paradise Ultrasound Renal Denervation (uRDN) system for the treatment of ...

Chronic kidney disease claims over 50,000 lives each year, and most victims never saw it coming. National Kidney Month is ...

The US Food and Drug Administration (FDA) has approved Medtronic's Symplicity Spyral renal denervation system for the treatment of hypertension, the company has announced. The Symplicity Spyral system ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at three years. The completion of five-year follow-up marks an important ...

Please provide your email address to receive an email when new articles are posted on . For the first time in its history, the U.S. Renal Data System Annual Data Report included a chapter devoted to ...